Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension. Baxdrostat is a highly selective, oral, small molecule ...

WILMINGTON, Del., July 14, 2025--Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically ...

In August 2025, Bayer announced a study of researchers will check the medical history and current medications of the participants. They will also perform a complete health check-up of all the ...

A phase III trial of baxdrostat for primary aldosteronism is now underway. Developer AstraZeneca is also testing it as monotherapy for hypertension, and in combination with dapagliflozin (Farxiga) for ...

Baxdrostat-related increases in the potassium level to 6.0 mmol per liter or greater occurred in 2 patients, but these increases did not recur after withdrawal and reinitiation of the drug.

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial, indicating that the highly selective aldosterone synthase inhibitor (ASI), baxdrostat, significantly reduced the mean ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a much-needed fillip on Monday.

Anglo-Swedish pharma giant AstraZeneca PLC has agreed to buy CinCor Pharma Inc., including global rights to its baxdrostat cardiorenal drug, for an upfront transaction value of around $1.3 billion.

Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension. Baxdrostat is a highly selective, oral, small molecule ...

Baxdrostat is a potential first-in-class, highly selective aldosterone synthase inhibitor (ASI) that targets the hormone driving elevated blood pressure and increased cardiovascular and renal risk.